2014 Press Releases


Keyword Search
2017 | 2016 | 2015 | 2014
DateTitle 
12/02/14Tocagen Appoints Franklin M. Berger, CFA, to the Board of Directors
SAN DIEGO – (December 2, 2014) — Tocagen Inc. a clinical-stage selective cancer immunotherapy company, today announced that Franklin M. Berger, CFA, has been appointed to the board of directors. Mr. Berger will also serve as the chairman of a newly formed audit committee responsible for overseeing Tocagen’s accounting, financial reporting, disclosure and financial risk management activities. Mr. Berger is a biotechnology industry analyst with over 25 years of experience in capital markets and fi... 
Printer Friendly Version
11/18/14Toca 511 & Toca FC Survival and PFS-6 Data Surpasses Published Benchmarks
Interim Data Show Increased Median Overall Survival of Brain Cancer Patients Treated with Tocagen’s Toca 511 & Toca FC, Compared to Published Benchmarks Results Presented at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology MIAMI – November 18, 2014 — Tocagen Inc. today announced that interim data showed increased median overall survival and progression free survival at six months for recurrent high grade glioma (HGG) patients treated with Toca 511 &a... 
Printer Friendly Version
11/14/14 Tocagen Appoints Faheem Hasnain as Chairman of the Board of Directors
Tocagen Appoints Faheem Hasnain as Chairman of the Board of Directors Builds Expert Independent Board As Company Advances Towards Late-Stage Brain Cancer Trials SAN DIEGO, – November 14, 2014 – Tocagen Inc., a clinical-stage selective cancer immunotherapy company, today announced that Faheem Hasnain, president and chief executive officer of Receptos, Inc. (Nasdaq: RCPT), has been appointed as chairman of the board of directors. “Faheem’s impressive track record and extensive experience leading ... 
Printer Friendly Version